- Home
- NTHI vs BIOA Comparison
NTHI vs BIOA Comparison
Compare NTHI & BIOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTHI
- BIOA
- Stock Information
- Founded
- NTHI 2008
- BIOA 2015
- Country
- NTHI United States
- BIOA United States
- Employees
- NTHI N/A
- BIOA N/A
- Industry
- NTHI Biotechnology: Pharmaceutical Preparations
- BIOA Biotechnology: Pharmaceutical Preparations
- Sector
- NTHI Health Care
- BIOA Health Care
- Exchange
- NTHI Nasdaq
- BIOA Nasdaq
- Market Cap
- NTHI 211.9M
- BIOA 175.7M
- IPO Year
- NTHI N/A
- BIOA 2024
- Fundamental
- Price
- NTHI $9.80
- BIOA $7.57
- Analyst Decision
- NTHI
- BIOA Hold
- Analyst Count
- NTHI 0
- BIOA 4
- Target Price
- NTHI N/A
- BIOA $9.00
- AVG Volume (30 Days)
- NTHI 42.0K
- BIOA 621.6K
- Earning Date
- NTHI 11-19-2025
- BIOA 11-06-2025
- Dividend Yield
- NTHI N/A
- BIOA N/A
- EPS Growth
- NTHI N/A
- BIOA N/A
- EPS
- NTHI N/A
- BIOA N/A
- Revenue
- NTHI $59,990.00
- BIOA $3,863,000.00
- Revenue This Year
- NTHI N/A
- BIOA N/A
- Revenue Next Year
- NTHI N/A
- BIOA N/A
- P/E Ratio
- NTHI N/A
- BIOA N/A
- Revenue Growth
- NTHI N/A
- BIOA N/A
- 52 Week Low
- NTHI $3.20
- BIOA $2.88
- 52 Week High
- NTHI $25.00
- BIOA $24.66
- Technical
- Relative Strength Index (RSI)
- NTHI N/A
- BIOA 67.84
- Support Level
- NTHI N/A
- BIOA $7.25
- Resistance Level
- NTHI N/A
- BIOA $8.15
- Average True Range (ATR)
- NTHI 0.00
- BIOA 0.44
- MACD
- NTHI 0.00
- BIOA 0.17
- Stochastic Oscillator
- NTHI 0.00
- BIOA 70.99
About NTHI NeOnc Technologies Holdings Inc. Common Stock
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA).
About BIOA BioAge Labs Inc. Common Stock
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others.